- Conditions
- Advanced Solid Tumors, Glioblastoma, Soft Tissue Sarcoma (Excluding GIST), Endometrial Carcinoma, Epithelial Ovarian Carcinoma, Mesothelioma, Gastroenteropancreatic Neuroendocrine Tumor, SCLC, Gastric Carcinoma, Pancreatic Adenocarcinoma, Colorectal Carcinoma, Neuroendocrine Tumors
- Interventions
- Lurbinectedin, Irinotecan
- Drug
- Lead sponsor
- PharmaMar
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 316 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2025
- U.S. locations
- 4
- States / cities
- Santa Monica, California • Boston, Massachusetts • Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 865–888
of 5,151
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Melanoma, Malignant Melanoma
- Interventions
- CT-011
- Drug
- Lead sponsor
- Medivation, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 16
- States / cities
- New Haven, Connecticut • Tampa, Florida • Chicago, Illinois + 9 more
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- conventional surgery, brachytherapy, radiation therapy
- Procedure · Radiation
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 7 more
- Conditions
- Malignant Melanoma
- Interventions
- gp75 DNA vaccine
- Biological
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2004
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Sarcoma
- Interventions
- dactinomycin, busulfan, doxorubicin hydrochloride, etoposide, ifosfamide, melphalan, vincristine sulfate, autologous hematopoietic stem cell transplantation, conventional surgery, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- University of Leicester
- Other
- Eligibility
- Up to 49 Years
- Enrollment
- 1,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 88
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 80 more
- Conditions
- Malignant Melanoma
- Interventions
- CancerVax vaccine (CANVAXIN)
- Biological
- Lead sponsor
- CancerVax Corporation
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 670 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 51
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Anaheim, California + 43 more
- Conditions
- Solid Tumors
- Interventions
- Navlimetostat, Daraxonrasib, Temozolomide, Pumitamig, Pemetrexed, Carboplatin, Nab-paclitaxel, Gemcitabine, Paclitaxel, Cisplatin
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 254 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 16
- States / cities
- San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 10 more
- Conditions
- Cancer
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 25 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2014
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Ovarian Cancer, Merkel Cell Carcinoma, SCLC
- Interventions
- BB-10901
- Drug
- Lead sponsor
- ImmunoGen, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2011
- U.S. locations
- 6
- States / cities
- San Francisco, California • Las Vegas, Nevada • Columbus, Ohio + 3 more
- Conditions
- Melanoma (Skin)
- Interventions
- filgrastim, therapeutic autologous dendritic cells
- Biological
- Lead sponsor
- Baylor Health Care System
- Other
- Eligibility
- 21 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Uveal Melanoma
- Interventions
- Education for Intervention, Best Practice
- Behavioral
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Melanoma (Skin)
- Interventions
- comparative genomic hybridization, cytogenetic analysis, fluorescence in situ hybridization, immunohistochemistry staining method
- Genetic · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 314 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2009
- U.S. locations
- 27
- States / cities
- Chicago, Illinois • Cedar Rapids, Iowa • Boston, Massachusetts + 17 more
- Conditions
- Neuroblastoma, Medulloblastoma, Typical Teratoid Rhabdoid Tumor, Embryonal Tumor With Abundant Neuropil and True Rosettes, Ependymoblastoma, Medulloepithelioma
- Interventions
- eflornithine HCl
- Drug
- Lead sponsor
- Giselle Sholler
- Other
- Eligibility
- 0 Years to 30 Years
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
- Conditions
- Metastatic Melanoma
- Interventions
- Photoimmunotherapy
- Other
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Glioblastoma Multiforme
- Interventions
- Bevacizumab, BKM120
- Drug
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 8
- States / cities
- New Haven, Connecticut • Fort Myers, Florida • Orlando, Florida + 5 more
- Conditions
- Medullary Thyroid Cancer
- Interventions
- cabozantinib
- Drug
- Lead sponsor
- Exelixis
- Industry
- Eligibility
- 18 Years and older
- U.S. locations
- 5
- States / cities
- Stanford, California • Boston, Massachusetts • Detroit, Michigan + 2 more
- Conditions
- Neuroblastoma
- Interventions
- monoclonal antibody 3F8, sargramostim
- Biological
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 2 Years to 21 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1994 – 2005
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Neuroblastoma
- Interventions
- filgrastim, carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, mesna, vincristine sulfate, conventional surgery, peripheral blood stem cell transplantation, low-LET cobalt-60 gamma ray therapy, low-LET photon therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2005
- U.S. locations
- 7
- States / cities
- Los Angeles, California • San Francisco, California • Indianapolis, Indiana + 4 more
- Conditions
- Glioblastoma Multiforme
- Interventions
- ICT-107, Placebo DC
- Biological
- Lead sponsor
- Precision Life Sciences Group
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 25
- States / cities
- South Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 17 more
- Conditions
- Cancer
- Interventions
- Dabrafenib 150 mg twice a day (BID), Rabeprazole 40 mg once daily (OD), Rifampin 600 mg OD
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 3
- States / cities
- Goodyear, Arizona • Dallas, Texas • Tacoma, Washington
- Conditions
- Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma, Recurrent Ewing Sarcoma, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Kidney Wilms Tumor, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Refractory Ependymoma, Refractory Ewing Sarcoma, Refractory Glioma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma
- Interventions
- Laboratory Biomarker Analysis, Palbociclib, Pharmacological Study
- Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Months to 21 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 115
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 93 more
- Conditions
- Extragonadal Germ Cell Tumor, Ovarian Cancer, Teratoma, Testicular Germ Cell Tumor
- Interventions
- sunitinib malate
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Neuroblastoma, Melanoma, Osteosarcoma, Ewing Sarcoma
- Interventions
- Anti-GD2 antibody
- Biological
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Olfactory Neuroblastoma, Esthesioneuroblastoma
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 3 Years to 120 Years
- Enrollment
- 525 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland